XL-281
XL-281 (BMS-908662) is an orally active inhibitor for RAF kinase, with IC50s of 2.6, 4.5 and 6 nM, for CRAF, B-RAF, and B-RAFV600E, respectively. XL-281 exhibits antitumor activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 870603-16-0
- Formule: C24H19ClN4O4
- Masse moléculaire:462.89
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-10966
SB-590885BRAF/c-Raf Inhibitor -
HY-15246
TovorafenibRaf Kinase Inhibitor -
HY-109080
BelvarafenibRAF Inhibitor -
HY-10247
BRAF inhibitorB-Raf Inhibitor -
HY-112089
NaporafenibB/CRAF Inhibitor -
HY-145120
MosperafenibBRAF Inhibitor -
HY-15605
EncorafenibBRAF Inhibitor -
HY-14177
Raf inhibitor 1Raf Inhibitor -
HY-109574
Raf inhibitor 2Raf Kinase Inhibitor -
HY-10966R
SB-590885 (Standard)Reference Standard -
HY-18972
PlixorafenibBRAF Inhibitor -
HY-107779
BI-882370RAF Inhibitor
Activité biologique
Description
IC50 & Target
|
C-Raf 2.6 nM (IC50) |
B-Raf 4.5 nM (IC50) |
B-RafV600E 6 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SK-MEL19 | IC50 |
200 nM
Compound: 8; XL281; BMS-908662
|
Cytotoxicity against human SK-MEL-19 cells harboring BRAF mutant after 3 days
Cytotoxicity against human SK-MEL-19 cells harboring BRAF mutant after 3 days
|
[PMID: 29461827] |
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 870603-16-0
-
Masse moléculaire 462.89
-
Formule C24H19ClN4O4
-
SMILES
O=C(OC)NC1=NC2=CC=C(C3(O)N(C4=CC(Cl)=CC=C4C)C(C5=C3C=CC=C5)=O)C=C2N1
-
Synonyms
BMS-908662
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
XL-281 Related Classifications
HY-19343 Related Classifications
Powered by Bioz